G

Grifols SA
D

GRFS

10.110
USD
0.18
(1.76%)
مغلق
حجم التداول
0
الربح لكل سهم
1
العائد الربحي
-
P/E
37
حجم السوق
6,878,936,041
أصول ذات صلة
ALNY
ALNY
1.29
(0.39%)
329.01 USD
AMGN
AMGN
-2.01
(-0.65%)
306.66 USD
AZN
AZN
-1.055
(-1.43%)
72.640 USD
BMY
BMY
-0.525
(-1.07%)
48.455 USD
GSK
GSK
-0.250
(-0.65%)
37.965 USD
ICLR
ICLR
-7.920
(-4.06%)
187.080 USD
NVO
NVO
0.990
(1.40%)
71.720 USD
PFE
PFE
-0.555
(-2.19%)
24.810 USD
SNY
SNY
0.230
(0.46%)
50.370 USD
TAK
TAK
-0.185
(-1.26%)
14.465 USD
المزيد
الأخبار المقالات

العنوان: Grifols SA

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.